Jacobs Levy Equity Management
PASG icon

Jacobs Levy Equity Management’s Passage Bio PASG Stock Holding History

Jacobs Levy Equity Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,539
Closed -$576K – 1061
2021
Q4 		$576K Buy
+4,539
New +$741K ﹤0.01% 820

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Jacobs Levy Equity Management's PASG Position: Q1 2022 in Review

Jacobs Levy Equity Management sold out of Passage Bio (PASG) in Q1 2022, closing a stake of 4,539 shares — an estimated $576K sold.

Jacobs Levy Equity Management first reported a position in PASG in Q4 2021 and held it in 1 quarter. The position peaked at $576K in Q4 2021. 108 funds tracked by Wall St. Rank hold PASG as of Q1 2022.

  • Jacobs Levy Equity Management reported no remaining Passage Bio position as of Q1 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 4,539 Passage Bio shares in Q1 2022, an estimated $576K.
  • Jacobs Levy Equity Management first reported a position in Passage Bio in Q4 2021 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Passage Bio position peaked at $576K in Q4 2021.
  • 108 funds tracked by Wall St. Rank held Passage Bio as of Q1 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2022, filed 16 May 2022.